Experimental Hematology
Volume 38, Issue 9 , Pages 798-808.e2 , September 2010

Identification of E74-like factor 1 (ELF1) as a transcriptional regulator of the Hox cofactor MEIS1

  • Ping Xiang

      Affiliations

    • Terry Fox Laboratory, British Columbia Cancer Agency, Vancouver, British Columbia, Canada
    • ,
  • Chaoyu Lo

      Affiliations

    • Terry Fox Laboratory, British Columbia Cancer Agency, Vancouver, British Columbia, Canada
    • ,
  • Bob Argiropoulos

      Affiliations

    • Terry Fox Laboratory, British Columbia Cancer Agency, Vancouver, British Columbia, Canada
    • ,
  • C. Benjamin Lai

      Affiliations

    • Terry Fox Laboratory, British Columbia Cancer Agency, Vancouver, British Columbia, Canada
    • ,
  • Arefeh Rouhi

      Affiliations

    • Terry Fox Laboratory, British Columbia Cancer Agency, Vancouver, British Columbia, Canada
    • Institute of Experimental Cancer Research, Clinical Comprehensive Centre, Ulm University, Ulm, Germany
    • ,
  • Suzan Imren

      Affiliations

    • Terry Fox Laboratory, British Columbia Cancer Agency, Vancouver, British Columbia, Canada
    • ,
  • Xiaoyan Jiang

      Affiliations

    • Terry Fox Laboratory, British Columbia Cancer Agency, Vancouver, British Columbia, Canada
    • Department of Medical Genetics, University of British Columbia, Vancouver, British Columbia, Canada
    • ,
  • Dixie Mager

      Affiliations

    • Terry Fox Laboratory, British Columbia Cancer Agency, Vancouver, British Columbia, Canada
    • Department of Medical Genetics, University of British Columbia, Vancouver, British Columbia, Canada
    • ,
  • R. Keith Humphries

      Affiliations

    • Terry Fox Laboratory, British Columbia Cancer Agency, Vancouver, British Columbia, Canada
    • Department of Medicine, University of British Columbia, Vancouver, British Columbia, Canada
    • Corresponding Author InformationOffprint requests to: R. Keith Humphries, M.D., Ph.D., Terry Fox Laboratory, BC Cancer Agency, 675 West 10th Avenue, Vancouver, BC V5Z1L3, Canada

Received 1 June 2010 ,Revised 1 June 2010 ,Accepted 4 June 2010.

References 

  1. Spieker N, van Sluis P, Beitsma M, et al. The MEIS1 oncogene is highly expressed in neuroblastoma and amplified in cell line IMR32. Genomics. 2001;71:214–221
  2. Crijns AP, de Graeff P, Geerts D, et al. MEIS and PBX homeobox proteins in ovarian cancer. Eur J Cancer. 2007;43:2495–2505
  3. Mercader N, Leonardo E, Azpiazu N, et al. Conserved regulation of proximodistal limb axis development by Meis1/Hth. Nature. 1999;402:425–429
  4. Argiropoulos B, Yung E, Humphries RK. Unraveling the crucial roles of Meis1 in leukemogenesis and normal hematopoiesis. Genes Dev. 2007;21:2845–2849
  5. Winkelmann J, Schormair B, Lichtner P, et al. Genome-wide association study of restless legs syndrome identifies common variants in three genomic regions. Nat Genet. 2007;39:1000–1006
  6. Xiong L, Catoire H, Dion P, et al. MEIS1 intronic risk haplotype associated with restless legs syndrome affects its mRNA and protein expression levels. Hum Mol Genet. 2009;18:1065–10747
  7. Moskow JJ, Bullrich F, Huebner K, Daar IO, Buchberg AM. Meis1, a PBX1-related homeobox gene involved in myeloid leukemia in BXH-2 mice. Mol Cell Biol. 1995;15:5434–5443
  8. Nakamura T, Largaespada DA, Shaughnessy JD, Jenkins NA, Copeland NG. Cooperative activation of Hoxa and Pbx1-related genes in murine myeloid leukaemias. Nat Genet. 1996;12:149–153
  9. Kroon E, Krosl J, Thorsteinsdottir U, Baban S, Buchberg AM, Sauvageau G. Hoxa9 transforms primary bone marrow cells through specific collaboration with Meis1a but not Pbx1b. EMBO J. 1998;17:3714–3725
  10. Kroon E, Thorsteinsdottir U, Mayotte N, Nakamura T, Sauvageau G. NUP98-HOXA9 expression in hemopoietic stem cells induces chronic and acute myeloid leukemias in mice. EMBO J. 2001;20:350–361
  11. Pineault N, Buske C, Feuring-Buske M, et al. Induction of acute myeloid leukemia in mice by the human leukemia-specific fusion gene NUP98-HOXD13 in concert with Meis1. Blood. 2003;101:4529–4538
  12. Pineault N, Abramovich C, Ohta H, Humphries RK. Differential and common leukemogenic potentials of multiple NUP98-Hox fusion proteins alone or with Meis1. Mol Cell Biol. 2004;24:1907–1917
  13. Kawagoe H, Humphries RK, Blair A, Sutherland HJ, Hogge DE. Expression of HOX genes, HOX cofactors, and MLL in phenotypically and functionally defined subpopulations of leukemic and normal human hematopoietic cells. Leukemia. 1999;13:687–698
  14. Rozovskaia T, Feinstein E, Mor O, et al. Upregulation of Meis1 and HoxA9 in acute lymphocytic leukemias with the t(4: 11) abnormality. Oncogene. 2001;20:874–878
  15. Imamura T, Morimoto A, Takanashi M, et al. Frequent co-expression of HoxA9 and Meis1 genes in infant acute lymphoblastic leukaemia with MLL rearrangement. Br J Haematol. 2002;119:119–121
  16. Wong P, Iwasaki M, Somervaille TC, So CW, Cleary ML. Meis1 is an essential and rate-limiting regulator of MLL leukemia stem cell potential. Genes Dev. 2007;21:2762–2774
  17. Pineault N, Helgason CD, Lawrence HJ, Humphries RK. Differential expression of Hox, Meis1, and Pbx1 genes in primitive cells throughout murine hematopoietic ontogeny. Exp Hematol. 2002;30:49–57
  18. Hisa T, Spence SE, Rachel RA, et al. Hematopoietic, angiogenic and eye defects in Meis1 mutant animals. EMBO J. 2004;23:450–459
  19. Milne TA, Martin ME, Brock HW, Slany RK, Hess JL. Leukemogenic MLL fusion proteins bind across a broad region of the Hox a9 locus, promoting transcription and multiple histone modifications. Cancer Res. 2005;65:11367–11374
  20. Boyer LA, Plath K, Zeitlinger J, et al. Polycomb complexes repress developmental regulators in murine embryonic stem cells. Nature. 2006;441:349–353
  21. Esparza SD, Chang J, Shankar DB, Zhang B, Nelson SF, Sakamoto KM. CREB regulates Meis1 expression in normal and malignant hematopoietic cells. Leukemia. 2008;22:665–667
  22. Horman SR, Velu CS, Chaubey A, et al. Gfi1 integrates progenitor versus granulocytic transcriptional programming. Blood. 2009;113:5466–5475
  23. Hu YL, Fong S, Ferrell C, Largman C, Shen WF. HOXA9 modulates its oncogenic partner Meis1 to influence normal hematopoiesis. Mol Cell Biol. 2009;29:5181–5192
  24. Matys V, Fricke E, Geffers R, et al. TRANSFAC: transcriptional regulation, from patterns to profiles. Nucleic Acids Res. 2003;31:374–378
  25. Heinemeyer T, Wingender E, Reuter I, et al. Databases on transcriptional regulation: TRANSFAC, TRRD, and COMPEL. Nucleic Acids Res. 1998;26:364–370
  26. Bryne JC, Valen E, Tang MH, et al. JASPAR, the open access database of transcription factor-binding profiles: new content and tools in the 2008 update. Nucleic Acids Res. 2008;36(Database issue):D102–D106
  27. Li Q, Zhang M, Duan Z, Stamatoyannopoulos G. Structural analysis and mapping of DNase I hypersensitivity of HS5 of the beta-globin locus control region. Genomics. 1999;61:183–193
  28. Duan ZJ, Fang X, Rohde A, Han H, Stamatoyannopoulos G, Li Q. Developmental specificity of recruitment of TBP to the TATA box of the human gamma-globin gene. Proc Natl Acad Sci U S A. 2002;99:5509–5514
  29. Rouhi A, Gagnier L, Takei F, Mager DL. Evidence for epigenetic maintenance of Ly49A monoallelic gene expression. J Immunol. 2006;176:2991–2999
  30. Maksakova IA, Mager DL. Transcriptional regulation of early transposon elements, an active family of mouse long terminal repeat retrotransposons. J Virol. 2005;79:13865–13874
  31. Mueller BU, Pabst T. C/EBPalpha and the pathophysiology of acute myeloid leukemia. Curr Opin Hematol. 2006;13:7–14
  32. Oikawa T, Yamada T. Molecular biology of the Ets family of transcription factors. Gene. 2003;303:11–34
  33. Krivtsov AV, Twomey D, Feng Z, et al. Transformation from committed progenitor to leukaemia stem cell initiated by MLL-AF9. Nature. 2006;442:818–822
  34. Fukushima T, Miyazaki Y, Tsushima H, et al. The level of MEF but not ELF-1 correlates with FAB subtype of acute myeloid leukemia and is low in good prognosis cases. Leukemia Res. 2003;27:387–392
  35. Hollenhorst PC, Shah AA, Hopkins C, Graves BJ. Genome-wide analyses reveal properties of redundant and specific promoter occupancy within the ETS gene family. Genes Dev. 2007;21:1882–1894
  36. Xie X, Lu J, Kulbokas EJ, Golub TR, et al. Systematic discovery of regulatory motifs in human promoters and 3′ UTRs by comparison of several mammals. Nature. 2005;434:338–345
  37. Aittomäki S, Yang J, Scott EW, Simon MC, Silvennoinen O. Molecular basis of Stat1 and PU.1 cooperation in cytokine-induced Fcγ receptor I promoter activation. Int Immunol. 2004;16:265–274
  38. Garrett-Sinha LA, Dahl R, Rao S, Barton KP, Simon MC. PU.1 exhibits partial functional redundancy with Spi-B, but not with Ets-1 or Elf-1. Blood. 2001;97:2908–2912
  39. Hollenhorst PC, Jones DA, Graves BJ. Expression profiles frame the promoter specificity dilemma of the ETS family of transcription factors. Nucleic Acids Res. 2004;21:5693–5702
  40. Taub JW, Huang X, Matherly LH, et al. Expression of chromosome 21-localized genes in acute myeloid leukemia: differences between Down syndrome and non-Down syndrome blast cells and relationship to in vitro sensitivity to cytosine arabinoside and daunorubicin. Blood. 1999;94:1393–1400
  41. Marcucci G, Baldus CD, Ruppert AS, et al. Overexpression of the ETS-related gene, ERG, predicts a worse outcome in acute myeloid leukemia with normal karyotype: a Cancer and Leukemia Group B study. J Clin Oncol. 2005;23:9234–9242
  42. Stankiewicz MJ, Crispino JD. ETS2 and ERG promote megakaryopoiesis and synergize with alterations in GATA-1 to immortalize hematopoietic progenitor cells. Blood. 2009;113:3337–3347
  43. Lasa A, Carnicer MJ, Aventín A, et al. MEIS 1 expression is downregulated through promoter hypermethylation in AML1-ETO acute myeloid leukemias. Leukemia. 2004;18:1231–1237
  44. Graves BJ, Petersen JM. Specificity within the ets family of transcription factors. Adv Cancer Res. 1998;75:1–55

PII: S0301-472X(10)00241-9

doi: 10.1016/j.exphem.2010.06.006

Experimental Hematology
Volume 38, Issue 9 , Pages 798-808.e2 , September 2010

Article Tools

* Image Usage & Resolution